Programmed Death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) Market Research And Global Outlook 2017 to 2030

PD-L1 NSCLC: Disease Understanding and Treatment Algorithm PD-L1 NSCLC Overview Non-small cell lung cancer (NSCLC) is the most common type of lung cancer accounted for approximately 85% of all lung cancers

Programmed Death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC)-Market Insights, Epidemiology And Market Forecast—2030

Global Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC)-Market Insights, Epidemiology and Market Forecast-2030 report delivers an in-depth understanding of the PD-L1 NSCLC ,historical and forecasted epidemiology as well as the PD-L1 NSCLC market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The PD-L1 NSCLC market report provides current treatment practices, emerging drugs, PD-L1 NSCLC market share of the individual therapies, current and forecasted PD-L1 NSCLC market size from 2017 to 2030 segmented by seven major markets. The Report also covers current PD-L1 NSCLC treatment practices/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

Geography Covered
� The United States
� EU5 (Germany, France, Italy, Spain and the United Kingdom)
� Japan

(Special Offer: Available Flat 30% Discount for a limited time only):

Get a Free Sample Copy of the Report:

PD-L1 NSCLC Drugs Uptake
Keytruda is expected to major share from the overall market of PD-L1 NSCLC due to physician�s familiarities and established clinical profile. On the other hand, Opdivo is expected to take second highest share from the market due to its dominancy in second-line line setting.
Access and Reimbursement Scenario in PD-L1 NSCLC Therapies
As per the recommendation of some drugs by NICE which are approved for NSCLC, theaccess and reimbursement scenario for therapies in the UK are listed as

In July 2018, Keytruda was recommended for, untreated PD L1-positive metastatic NSCLC in adults whose tumors express PD L1 (with at least a 50% tumor proportion score) and have no EGFR- or ALK-positive mutations.
In January 2017, Keytruda is recommended for treating locally advanced or metastatic PD L1 positive NSCLC in adults who have had at least one chemotherapy (and targeted treatment if they have an EGFR- or ALK-positive tumor).
In May 2019, Durvalumab is recommended for treating locally advanced unresectable NSCLC in adults whose tumors express PD L1 on at least 1% of tumor cells and whose disease has not progressed after platinum-based chemoradiation.
� It was stated by NICE that Atezolizumab +bevacizumab is recommended for metastatic NSCLC in adults who have not had treatment for their metastatic NSCLC before and whose PD-L1 tumor proportion score is between 0% and 49%.
To keep up with current market trends, we take KOLs and SMEs opinion working in PD-L1 NSCLC domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or PD-L1 NSCLC market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the PD-L1 NSCLC Market by using various Competitive Intelligence tools that includes  SWOT analysis, PESTLE analysis, Porters five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Study Period: 2017-2030
PD-L1 NSCLC: Disease Understanding and Treatment Algorithm
PD-L1 NSCLC Overview
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer accounted for approximately 85% of all lung cancers. It can be defined as any type of epithelial lung cancer other than SCLC. It is mainly subcategorized into adenocarcinomas, squamous cell carcinomas, large cell carcinomas and several other types that occur less frequently include adenosquamous carcinomas, and sarcomatoid carcinomas. In these subtypes adenocarcinoma accounts for highest number of cases, i.e., approximately 47% followed by Squamous Cell Carcinoma and Large Cell Carcinoma.
There are several mutations associated with NSCLC but the most common are EGFR, KRAS, ROS-1, BRAF, MET, PD-L1 expression and others. Among all the mutations Programmed death ligand 1 (PD-L1), accounted for approximately 50% of the total cases of NSCLC.
PD-L1 (also known as CD274), is considered an immune checkpoint facilitating anti-tumor suppression of the immune pathway. The expression of PD-L1 is observed on the surface of macrophages, antigen-presenting cells, B and T-lymphocytes, epithelial, muscle and endothelial cells, whereas PD-1 receptor is expressed predominantly by activated cytotoxic T cells. PD-L1 ligand binds to PD-1 receptor on activated T cells and this connection results in suppression of the immune system. PD-L1 have become routinely part of the clinical approach for management of NSCLC where elevated levels of PD-L1 expression observed on the cell surface of cancer cells.

Avail Discount at:

PD-L1 NSCLC Diagnosis
The diagnosis and staging of NSCLC are often done at the same time. A laboratory test is done to check for certain genes, proteins, or other molecules in a sample of tissue, blood, or other body fluid. Molecular tests check for certain gene or chromosome changes that occur in NSCLC.
PD-L1 NSCLC Treatment
PD-1/PD-L1 blocking antibodies therapy is recommended for the patients showing PD-L1 expressions. In recent years, immunotherapy has revolutionized and changed the standard of care in patients with NSCLC. Immune checkpoint inhibitors, fundamentally those that act by blocking PD-1 and its ligand, the PD-L1, have emerged as novel treatment strategies in NSCLC, demonstrating undoubted superiority over chemotherapy in terms of efficacy.
Several of these immune checkpoint modulators have recently gained regulatory approval for the treatment of advanced NSCLC, such as Opdivo (nivolumab), Tecentriq (atezolizumab), Keytruda (pembrolizumab, and recently, Imfinzi (durvalumab). Among all of the approved PD-1/PD-L1 inhibitors, the NSCLC therapy area is dominated by Keytruda (pembrolizumab), with revenues from this particular market helping the drug to achieve a hit status.
PD-L1 NSCLC Epidemiology
PD-L1 NSCLC Epidemiology division provides the insights about historical and current PD-L1 NSCLC patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Browse the report description and

What are the market factors that are explained in the report?

Key Strategic Developments: The study also includes the key strategic developments of the market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

Key Market Features: The report evaluates key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. In addition, the study offers a comprehensive study of the key market dynamics and their latest trends, along with pertinent market segments and sub-segments.

Analytical Tools: The Global Programmed Death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porter’s five forces analysis, SWOT analysis, feasibility study, and investment return analysis have been used to analyze the growth of the key players operating in the market.

Customization of the Report: This report can be customized as per your needs for additional data up to 3 companies or countries or 40 analyst hours.

About Us:

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc.MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

How we have factored the effect of Covid-19 in our report:

All the reports that we list have been tracking the impact of COVID-19. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

Contact Us:

IrfanTamboli (Head of Sales) – Market Insights Reports

Phone: + 1704 266 3234 | +91-750-707-8687 |



Back to top button